All In Biotech

Free tool

FAERS Monitor: Amicar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 015230 or its brand name (Amicar, Aminocaproic Acid). Reports on generic versions are filed under their own applications.

Reports

801

Serious

606

76% of reports

Hospitalization

304

Death reported

144

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemorrhage144
  • off label use67
  • epistaxis61
  • drug ineffective52
  • fall40
  • death37
  • mouth haemorrhage37
  • haemarthrosis36
  • hypotension30
  • contusion29
  • pain29
  • thrombocytopenia27
  • pyrexia26
  • head injury22
  • anaemia20

Reports by year received

View as table
YearReports
20043
20052
200612
20075
20089
200919
201017
201134
201212
201317
201418
201528
201624
201716
201817
201949
202045
202143
202237
202378
2024105
2025113
202698

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,358 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mouth haemorrhageSignal37133.297.14,701
haemarthrosisSignal36105.976.93,624
haemorrhageSignal14436.231.24,914
epistaxisSignal6121.416.81,171
head injurySignal2218.312.1342
contusionSignal297.95.5169
thrombocytopeniaSignal276.34.4117
hypotensionSignal303.92.863
fallSignal403.22.358
anaemiaSignal202.81.821
off label useSignal672.01.634
pyrexia262.01.412
pain291.20.91
death371.10.80
drug ineffective521.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.